Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CeriBell, Inc. (Nasdaq: CBLL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a medical technology company focused on point-of-care electroencephalography (EEG) for serious neurological conditions, CeriBell uses its filings to report financial performance, material agreements, intellectual property actions, and key product milestones related to the Ceribell System.
Investors can review periodic reports and current reports on Form 8-K that describe quarterly financial results, including separate disclosure of product revenue and subscription revenue, as well as updates on cash, marketable securities, and operating expenses. Filings also cover material definitive agreements, such as the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University for patent rights related to portable brain wave devices, and the Corporate Supply Agreement with Shenzhen Everwin Precision Technology Co., Ltd. and affiliates for EEG headband supply and related licenses.
Other 8-K filings document regulatory and legal developments, including announcements of FDA 510(k) clearance for the Clarity® algorithm in neonatal seizure detection, clearance for the company’s delirium monitoring solution, and the FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor. Filings also describe patent infringement complaints filed against Natus Medical Incorporated and related subsidiaries, as well as lease amendments for office space in Sunnyvale, California and governance changes such as the election of new directors.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand financial trends, material contracts, regulatory events, and intellectual property issues affecting CBLL. Users can also track insider-related disclosures when available through forms such as Form 4, and refer to annual reports on Form 10-K and quarterly reports on Form 10-Q for deeper insight into CeriBell’s business, risk factors, and operations.
Raymond Woo filed a notice to sell 11,112 common shares of CBLL under Rule 144. The planned sale, through Fidelity Brokerage Services on NASDAQ, has an aggregate market value of $231,129.60 and is targeted for approximately February 2, 2026.
The shares were acquired by exercising stock options on February 2, 2026 that were originally granted on July 7, 2021 and February 16, 2023, for 1,472 and 9,640 shares respectively, paid in cash. Over the past three months, Woo has sold 11,112 CBLL common shares on each of November 11, 2025, December 1, 2025, and January 2, 2026, for gross proceeds of $136,496.56, $184,424.30, and $235,228.09.
Josef Parvizi Trust, an entity associated with Ceribell director Josef Parvizi, sold 25,000 shares of Ceribell common stock on January 15, 2026 at a weighted average price of $22.94 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2025, meaning the trades were pre-arranged rather than discretionary on the trade date. After the sale, the Josef Parvizi Trust held 747,652 shares, while the Innovation ACP Trust held 907,911 shares and the ACP 2021 Trust held 369,088 shares, all reported as indirectly owned, with beneficial ownership disclaimed except to the extent of pecuniary interest.
A shareholder has filed a notice of proposed sale under Rule 144 for 25,000 shares of common stock, to be sold through Fidelity Brokerage Services LLC on NASDAQ around 01/15/2026. The filing lists an aggregate market value of $573,453.07 for these shares and states that there are 37,095,690 common shares outstanding.
The 25,000 shares to be sold were originally acquired as pre-IPO shares from the issuer on 08/29/2014 for cash. The document also reports that the Josef Parvizi Trust sold 25,000 common shares on 12/08/2025 for gross proceeds of $506,467.06 and another 25,000 common shares on 12/15/2025 for gross proceeds of $538,650.34.
Ceribell, Inc. insider activity: Chief Revenue Officer Joseph S. Manni reported a disposition of 660 shares of Ceribell common stock on November 20, 2025, at a price of $13.64 per share under transaction code "F." After this transaction, he beneficially owned 27,401 shares of common stock in direct ownership. A footnote explains that this total includes 300 shares previously acquired through the company’s Employee Stock Purchase Plan on July 31, 2025.
Ceribell, Inc. Senior VP, Finance and PAO David Foehr reported multiple equity transactions in company stock. On November 20, 2025, 484 shares of common stock were disposed of at $13.64 per share in a transaction coded "F," typically used for tax withholding. On January 5, 2026, he exercised stock options to acquire 3,403 and 2,153 shares of common stock at an exercise price of $4.7 per share and then sold 3,403 and 2,153 shares at $22.6 per share the same day. These sales were made under a pre-arranged Rule 10b5-1 trading plan. After the reported transactions, he held 18,900 shares of common stock directly.
Ceribell, Inc. President and CEO Xingjuan (Jane) Chao, who is also a director, reported multiple equity transactions in Ceribell common stock and stock options. On 11/20/2025, 2,887 shares of common stock were withheld at $13.64 per share in a transaction coded "F", leaving 795,248 shares held directly. On 01/05/2026, she exercised stock options at an exercise price of $4.70 per share and sold the resulting shares in several transactions pursuant to a Rule 10b5-1 trading plan, including a sale of 54,000 shares at a weighted average price of $21.31. After these trades, she directly owned 741,248 shares of common stock. Separately, an additional 369,088 shares of common stock are reported as indirectly owned through the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership except to the extent of her pecuniary interest. The underlying options reported have expiration dates in 2033 and vest monthly from April 1, 2023.
Ceribell, Inc. filed a Form 4 reporting recent stock transactions by its Chief Technology Officer. On 11/20/2025, 687 shares of common stock were withheld or disposed of at $13.64 in a transaction coded “F,” typically used for tax withholding.
On 01/02/2026, the CTO exercised multiple stock options and immediately sold the resulting shares in pre-planned trades under a Rule 10b5-1 trading plan. Options with exercise prices of $2.24 and $4.70 were exercised in blocks of 1,472, 3,025 and 6,615 shares, followed by sales coded “S” at weighted-average prices of $21.29, $21.18 and $21.16.
After these transactions, the reporting person beneficially owned 167,317 shares of Ceribell common stock, which includes 300 shares acquired through the company’s employee stock purchase plan. The filing also notes outstanding stock options that are vested or continue to vest over time, extending to expiration dates in 2029 and 2033.
Ceribell, Inc. director Rebecca B. Robertson reported an option exercise and share sale. On January 2, 2026, she exercised a stock option for 2,500 shares of common stock at $2.24 per share, then sold 2,500 common shares at $21.89 on the same date. After these transactions, she directly held 19,576 shares of common stock and 7,650 stock options. The filing notes that the transactions were made under a Rule 10b5-1 trading plan that she had previously adopted, and that the stock option is fully vested and currently exercisable.
Ceribell, Inc. director Rebecca B. Robertson reported a sale of common stock and corrected a prior insider filing. On 06/17/2025, she sold 7,445 shares of Ceribell common stock at a weighted average price of $17.63, in transactions executed under a pre-established Rule 10b5-1 trading plan. After this sale, she beneficially owned 21,230 shares of common stock directly. This amended Form 4 removes a previously reported transaction on 06/18/2025 for 11,188 shares that was incorrectly attributed to her, with no other changes made.
Ceribell, Inc. director Josef Parvizi reported an insider stock sale. On 12/15/2025, a trust related to him sold 25,000 shares of Ceribell common stock at a weighted average price of $21.49 per share in transactions executed under a Rule 10b5-1 trading plan. After this sale, he indirectly held 772,652 shares through the Josef Parvizi Trust, 907,911 shares through the Innovation ACP Trust, and 369,088 shares through the ACP 2021 Trust. He serves as trustee or co-trustee of these trusts and may be deemed to have beneficial ownership of the securities, but disclaims beneficial ownership except to the extent of his pecuniary interest.